Compass Therapeutics, Inc. (CMPX) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-05
How it makes money
It earns no revenue currently and depends on future product sales to healthcare providers.
It will earn revenue by selling oncology drugs to patients and healthcare payers; successful clinical trial outcomes and regulatory approvals drive this result.
The company is in the clinical stage of development. It aims to sell antibody-based therapeutics to patients, though it does not expect to generate revenue from product sales for several years.
What protects it: the moat
Management claims its proprietary technology and intellectual property will protect its pipeline.
It asserts that its StitchMabsTM technology and the intellectual property rights it has secured for its product candidates will provide a competitive advantage.
What growth costs
It must reinvest heavily in clinical development and research to advance its candidates.
To grow and reach commercialization, the company must fund research, clinical trials, and eventually build manufacturing and sales infrastructure.
What could damage it
Failure to obtain regulatory approval will prevent the company from generating revenue.
The company's ability to sell products is contingent on regulatory success. If its candidates fail to get approval, the revenue-generating path is blocked.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.